Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1

NCT07486934 is registered in ClinicalTrials.gov with Dyne Therapeutics as lead sponsor.

NCT NCT07486934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07486934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
Lead sponsor
Dyne Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
May 14, 2026
Completion date
January 31, 2029
Enrollment
150 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

dm1, myotonic dystrophy, myotonic dystrophy type 1 (dm1), steinert, steinert disease